PLRX - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים Pliant Therapeutics

Pliant Therapeutics (PLRX) currently generates no revenue, remaining dependent on Bexotegrast trials. This daily chart of trailing twelve-month revenue changes from the GURU.Markets service reflects a trend where the level 0.00 represents the current value. High FDA barriers and patents protect the business, while its status as a scientific leader in pulmonary fibrosis therapy provides the company with impeccable authority among specialized physicians.
Pliant Therapeutics Inc (PLRX) - פילוחי מדדים ודוחות פיננסיים

Pliant Therapeutics (PLRX) develops selective integrin inhibitors to combat fibrosis, possessing significant pricing power. The rolling year-over-year revenue dynamics allow for a real-time assessment of the commercialization of these drugs. This metric measures the pace of sales expansion by comparing the current twelve months to the same period last year. An increase in the indicator confirms business scaling, while a decline signals weakening demand. By analyzing the relative change in rolling year-over-year revenue, an investor can observe actual market expansion.